
Please try another search
Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs. The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases. It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform. The company was formerly known as AegirBio AB (publ) and changed its name to Magnasense AB in July 2024. Magnasense AB was incorporated in 2019 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Fredrik Haglund | 50 | 2020 | Non-Independent Director |
Adam S. Cheifetz | - | 2024 | Member of Scientific Advisory Board |
William Vickery | 58 | 2022 | Independent Director |
Iain L. C. Chapple | - | 2024 | Member of Scientific Advisory Board |
Marco Witteveen | 56 | 2023 | CEO & Director |
Jens Umehag | 51 | 2024 | Non-Independent Chairman |
Michael Schwartz | 55 | 2024 | Non-Independent Director |
Melissa Grant | - | 2024 | Member of Scientific Advisory Board |
William J. Ferenczy | 70 | 2024 | Non- Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review